TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Freedom from Atrial Arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in levels of (-)-[2-14C]epicatechin-derived radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of Pediatric critical illness polyneuropathy/myopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in area under the glucose infusion rate (AUCGIR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to need for dopaminergic therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in memory from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in spatial working memory from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in attention from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in executive function from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 24 hour hydromorphone consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Behavioral Assessment System for Children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Range of Motion Measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Trunk Impairment Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Functional Reach Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Jamar Dynamometer Strength Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Canadian Occupational Performance Measure
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Uptake of Pre-exposure prophylaxis for HIV
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in ECG variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Menstrual Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Participant Bladder Pain Sensitivity From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caregiver's participation in cognitively stimulating activities
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: level of Th2 cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Detection of Command Following
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: related toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Alive and in care
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Patients With Adverse Drug Reactions (ADR) by Severity Class
Endpoint domain: Adverse events/effects
Primary endpoint: Time on Treatment With Gi(l)Otrif®
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to Progression With Gi(l)Otrif®
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of new users with previous diagnosis of Acne
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of new users with previous diagnosis of Hirsutism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Proportion of new users with previous diagnosis of other Hyperandrogenic Conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Correlation of drug PKs with clinical response and toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of severe liver toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of veno-occlusive disease
Endpoint domain: Adverse events/effects
Primary endpoint: Tumor infiltrating T cell (TIL) density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of Dose Limiting Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Dose Limiting Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Time Concentration Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection and delineation of tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Death or re-hospitalization for heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Change of CTC count during treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the time versus plasma concentration curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median Percent Change in Non-Inflammatory Lesion Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Prevention of intrahousehold transmission of influenza virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Use of potentially inappropriate medications, urinary catheter or physical restraints
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total number of hospital acquired complications related to cognitive impairment
Endpoint domain: Adverse events/effects
Primary endpoint: Beck Suicidal Ideation Scale (BSSI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Expression level of ERBB4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Forced Expiratory Volume in 1 second
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Patients Hospitalization Rate
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: postoperative rescue morphine consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants With Target Lesion Failure (TLF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from Baseline Neurocognitive Function at 10 weeks - Hopkins Verbal Learning Test-Revised (HVLT-R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline Neurocognitive Function at 10 weeks - Trail Making Test Part A and B (TMT A & B)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline Neurocognitive Function at 10 weeks - Controlled Oral Word Association Test (COWA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Efficacy of Ramipril of Neurocognitive Function at Baseline - Shipley Institute of Living Scale-Version 2 Vocabulary
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of the VAS for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain, by numeric rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain, by consumption of analgesics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: return of function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Self-Management outcomes
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in Transitions of Care
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Change in Patient-Centredness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to initiating enteral feeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Contact Lens Dry Eye Questionnaire (CLDEQ-8) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 5-HT2a receptor occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Medication possession ratio (MPR) at least 95%
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Glucose Regulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain Visual Analog Score (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Reported Outcomes Measurement Information System (PROMIS) Upper Extremity Scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of sweating intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic relationship
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of HAPIN Defined Severe Pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Length-for-age z-score 2 standard deviations below the standard
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Child Linear Growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Caregiver Reported Early Childhood Development Instrument (CREDI) Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: therapeutic ACT retention rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Noninferiority of vaginal self-sampling for gonorrhea/chlamydia diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in t-PA use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Assessment of appropriateness of use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical pregnancy rate (CPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Patient Response to Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Arterial Recanalization Measured by TICI Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Device-related and Procedure-related Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in the Hopkins Symptom Checklist 90-Revised (SCL 90-R) scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: KSADS Mania Rating Scale (KMRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: KSADS Depression Section (KDRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alpha Amylase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Penn Alcohol and Craving Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Alcohol and Drug Use Consequences Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area under the plasma concentration-time curve from time 0 to the time of last quantifiable concentration (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change measure of Serum creatine kinase blood test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change measure of Countermovement jump test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change measure of 1-Repetition Maximum test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change measure of Visual Analogue Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area under the curve of endogenous glucose production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Opioid Craving Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Morphine Equivalent Doses
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Six-month Progression-free Survival (PFS6)
Endpoint domain: Mortality/survival
Primary endpoint: Clinical course of ischemic colitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Medication incidents
Endpoint domain: Adverse events/effects
Primary endpoint: Elevated levels of mucosal innate immune activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Medium-term health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: clinical treatment success as assessed by goniometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment satisfaction using the Patient or Physician Global Assessment and Satisfaction questionnaires
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in 6minWT distance walked
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in GMFM-88: total score and Dimensions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Risky Driving Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Unsafe Driving Behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of digital smartphone cervicograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consumption of clotting factor concentrate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: endogenous molecular profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percentage of Participants With None or Mild in GL Severity at Maximum Frown
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With None or Mild in FHL Severity at Maximum Eyebrow Elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With None or Mild in LCL Severity at Maximum Smile Effort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success rate of treatment protocols
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anastomosis leakage rate
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of severe maternal anaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportions of nutrition and WASH behaviours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI Lesion Visualization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant utilization of clinical resources
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Upper extremity muscle strength of right arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Upper extremity muscle strength of left arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Depth of invasion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of postoperative ovarian adhesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Subjective Well-being Under Neuroleptic (SWN-20) Scale Total Score at Week 24
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Respiratory Function Tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Blood products transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline in self-reported sleep duration in hours
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change from baseline in self-reported sleep quality
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change from baseline in self-reported fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: incidence of BRCA1/2, PALB2, PTEN mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Non-HDL Cholesterol, HDL Cholesterol, TG Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Patients Showing Sensitization Reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of postponed elective surgeries
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Quantity of lacrimal film
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact of symptoms on Activities of Daily Living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of Pressure Ulcers (PU) Category II, III, IV, Unstageable, Deep Tissue Injury (DTI)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Incontinence-associated Dermatitis (IAD)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Intertrigo
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Skin Tears (ST)
Endpoint domain: Adverse events/effects
Primary endpoint: Local Tumor Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Levels of adipokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adjacent segment degeneration (ASDeg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjacent segment disease (ASDis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency, type, and severity of treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean Change in the cfPWV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes from Baseline visual analog pain scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Ultrasound Images from Baseline Condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in TG concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Modified Rankin Scale at day 90
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Modified Rankin Scale at 7 days after discharge
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Total amount of administered fentanyl
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct position of DLT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proper lung deflation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Dose-normalized AUC of total curcuminoids plasmatic concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep quality and quantity
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Participants With Adverse Events by Grade
Endpoint domain: Adverse events/effects
Primary endpoint: Participants With Reduction in Plasma Cholestane-3β
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Participants With Reduction in Plasma Bile Acid B (5α)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Participants With Reduction in C-Triol (6β-triol)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bone Mass Density (BMD) at Total Hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of additional patient-controlled bolus of ropivacaine 0.2% (consumption in ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: paroxetine area under the curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With MRI Positivity- Global Assessment Positive
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With MRI Positivity- ASAS Positive
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With MRI Positivity- SPACE Positive
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With MRI Positivity- Morpho Positive
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain network stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neurotransmitter production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Self-reported pain during the lumbar puncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to the First Occurrence of a Component of the Composite Renal Endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Safety (clinical and laboratory parameters)
Endpoint domain: Adverse events/effects